LGND · Ligand Pharmaceuticals Incorpor
$300.53
-0.41% last session
End-of-day data · updated 2026-07-28
Market cap
$6B
Enterprise value
$6B
Trailing P/E
38.8
Forward P/E
25.2
Dividend yield
—
Beta
0.98
Avg volume
0M
Employees
0K
2D change
—
5D change
-1.54%
10D change
-1.94%
30D change
-2.01%
60D change
28.25%
MTD change
-4.65%
YTD change
57.35%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LGND
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-15
Latest call per bank · past 12 months
RBC Capital
Outperform$340
+13.1% vs priceBank of America
Buy$388
+29.1% vs priceCitigroup
Buy$282
-6.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-15 | RBC Capital | Maintains | Outperform | $262 → $340 |
| 2026-07-09 | Bank of America | Maintains | Buy | $266 → $388 |
| 2026-07-08 | Stifel | Maintains | Buy | $255 → $332 |
| 2026-05-08 | RBC Capital | Maintains | Outperform | $252 → $262 |
| 2026-04-30 | HC Wainwright & Co. | Maintains | Buy | $243 → $289 |
| 2026-04-28 | RBC Capital | Maintains | Outperform | $235 → $252 |
| 2026-04-15 | Citigroup | Maintains | Buy | $276 → $282 |
| 2026-04-14 | HC Wainwright & Co. | Maintains | Buy | $239 → $243 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.8% above the 50-day MA ($269.96).
- Price vs 200-day MA: Trading 35.9% above the 200-day MA ($218.00).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-3.91) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($131.58) and high ($322.61).
LGND Price Chart
Loading chart for LGND…
Fundamentals
About Ligand Pharmaceuticals Incorpor
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.